Sanofi (NASDAQ:SNY) Shares Sold by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. decreased its stake in shares of Sanofi (NASDAQ:SNY) by 18.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,006 shares of the company’s stock after selling 221 shares during the quarter. Pinnacle Bancorp Inc.’s holdings in Sanofi were worth $49,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares during the last quarter. Geode Capital Management LLC lifted its stake in Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after acquiring an additional 16,780 shares during the period. GFS Advisors LLC boosted its holdings in shares of Sanofi by 1,017.9% in the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after acquiring an additional 11,655 shares during the last quarter. Legacy Capital Wealth Partners LLC increased its stake in shares of Sanofi by 114.2% in the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after acquiring an additional 12,942 shares during the period. Finally, Icon Wealth Advisors LLC raised its holdings in shares of Sanofi by 7,954.4% during the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after purchasing an additional 289,144 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $50.70 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm’s 50 day simple moving average is $48.49 and its 200-day simple moving average is $52.09. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The stock has a market capitalization of $128.66 billion, a price-to-earnings ratio of 25.86, a PEG ratio of 1.17 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the company earned $2.55 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. Analysts expect that Sanofi will post 3.94 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.